A short news article about a university–industry licensing deal that lets a biotech develop an aging‑linked protein therapy toward clinical testing for cognitive impairment.
Key Takeaways
- Agreement supersedes and expands the license Jocasta previously acquired from Unity Biotechnology
- Α-klotho is a naturally occurring protein whose levels decline with age
- Making it one of the most closely watched targets in aging biology